Health, Economic Analysis and Clinical Aspects of Patients With Neurological Disabilities in Enteral Nutrition With Dedicated Formula. The Role of Nissen's Fundoplication in the Management of Gastroesophageal Reflux
NCT05068089 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 360
Last updated 2021-10-22
Summary
Nutritional difficulties are common in children with neurodisabilities and can be associated with malnutrition and gastrointestinal diseases, such as gastro-esophageal reflux disease (GERD) and constipation. Neurological disorders can be divided into two main categories: progressive (neurodegenerative, mitochondrial disease) and non-progressive (cerebral palsy) neurodisabilities; nature of the disorders can impair on the nutritional status of these children. In 2017, ESGHAN published guidelines with specific nutritional claims. Approximately 46%-90% of children with neurodisabilities suffer from malnutrition and an enteral feeding is necessary to reach the nutritional requirements. In addition, a relevant issue for these children is GERD, reaching up to 70% prevalence. The treatment of GERD could be based on pharmacological therapy (protonic pomp inhibitor, PPI), on nutritional treatment (changing type of formula) or on surgical treatment (Nissen Fundoplication). European guidelines for GERD recommend PPI as the first line, with fundoplication being considered in cases of failure of optimized medical therapy. Enteral feeding can be considered in order to avoid malnutrition and is justified when other efforts to increase nutritional intake. Enteral feeding can be provided by nasal tube at the beginning, but a gastrostomy feeding tube would be preferred for a long-term nutrition (greater than six weeks). A jejunal tube can be introduced through the gastrostomy; jejunal feeding is appropriate in patients with recurrent vomiting and/or tube feeding-related aspiration, severe gastroesophageal reflux, and gastroparesis. Different types of formulas can be used for enteral nutrition and can be offered by nasal tube, percutaneous endoscopic gastrostomy (PEG) or percutaneous endoscopic jejunostomy (PEJ). Whey-based formulas have been shown to empty from the stomach more rapidly than casein-based formulas, which may be helpful for patients presenting with delayed gastric emptying. Use of peptide-based, 100% whey protein formulas are associated with improved feeding tolerance, increased consistency in meeting nutritional needs, and a reduction in gastrointestinal issues associated with vomiting and aspiration of feeds. For these reasons, the aim of this study is to retrospectively evaluate the role of different formulas against Nissen fundoplication, regarding tolerance, utility, applicability and safeness of these products, by performing a cost analysis.
Conditions
- Gastro-Esophageal Reflux
- Fundoplication
Interventions
- PROCEDURE
-
Nissen fundoplication
Nissen fundoplication, numbers, reasons and length of hospitalizations, gastrointestinal symptoms and survival
- BIOLOGICAL
-
Enteral nutrition
Type and switch of enteral nutrition formula (tube, PEG, PEJ)
Sponsors & Collaborators
-
Nestlé Health Science Spain
collaborator INDUSTRY -
Bambino Gesù Hospital and Research Institute
lead OTHER
Eligibility
- Min Age
- 29 Days
- Max Age
- 17 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-11-01
- Primary Completion
- 2022-02-28
- Completion
- 2022-04-30
Countries
- Italy
Study Locations
More Related Trials
-
Gastric Accommodation and Gastroesophageal Reflux
NCT01078064 ·Status: TERMINATED
-
Prevalence and Natural History of Functional Gastrointestinal Disorders Among At-risk Infants.
NCT06031025 ·Status: RECRUITING
-
Endoloop Mediated Cardioplication to Treat Gastroesophageal Reflux Disease
NCT06153901 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Functional Endoscopy in Neurogenic Dysphagia
NCT01995929 ·Status: COMPLETED
-
Impact of Blocking the Glossopharyngeal Nerve on Gastroesophageal Reflux Disease
NCT06304870 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Evaluation of the Efficacy and Safety of Eolo in Patients With NERD
NCT07041060 ·Status: COMPLETED ·Phase: NA
-
Effect of Magnesium Alginate on Gastroesophageal Reflux in Infants.
NCT02806453 ·Status: UNKNOWN ·Phase: PHASE4
-
Esophageal Bolus Transit in Newborns With Gastroesophageal Reflux Disease
NCT02167984 ·Status: COMPLETED
-
Standardized Dysphagia Diet in Clinical Evaluation of Swallowing Function
NCT05634980 ·Status: UNKNOWN
-
Effect of Lidocaine Block on Gastroesophageal Reflux Disease
NCT06304142 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
The Effect of Esomeprazole and Fundoplication on Airways
NCT00994708 ·Status: COMPLETED ·Phase: PHASE3
-
Natural History of Gastroesophageal Reflux (GER) in Children < 12 Years of Age
NCT01048840 ·Status: COMPLETED
-
Comparison of Laparoscopic Hill and Laparoscopic Nissen Anti-Reflux Procedures
NCT01260935 ·Status: COMPLETED ·Phase: NA
-
Study of the NDO Endoscopic Plication System For the Treatment of Symptomatic Gastroesophageal Reflux Disease
NCT00587522 ·Status: COMPLETED ·Phase: NA
-
The Role of Gastroesophageal Reflux in Scleroderma Pulmonary Fibrosis
NCT02136394 ·Status: UNKNOWN
-
Prospective Evaluation of Symptom Resolution in Acid Versus Non-acid Reflux Disease Following Anti-reflux Surgery
NCT01241149 ·Status: TERMINATED ·Phase: NA
-
Post-Market Registry for the Evaluation of RefluxStop in GERD Treatment
NCT05870163 ·Status: RECRUITING
-
Thorcolumbar Kyphosis Patients With GERD
NCT04521985 ·Status: NOT_YET_RECRUITING
-
Management of Reflux After Sleeve Using Stretta
NCT02637713 ·Status: TERMINATED ·Phase: NA
-
Medical and Surgical Treatment of Esophageal Reflux
NCT00061724 ·Status: COMPLETED
-
FODMAPs and Refractory GERD
NCT02471989 ·Status: COMPLETED ·Phase: NA
-
Prevalence of Gastric Inlet Patches of the Cervical Esophagus.
NCT01056003 ·Status: UNKNOWN
-
Structure and Function of the Gastro-esophageal Junction
NCT01053585 ·Status: COMPLETED ·Phase: NA
-
Confocal Endomicroscopy for Non-Erosive Reflux Disease (CE NERD)
NCT02039869 ·Status: WITHDRAWN ·Phase: NA
-
Assessment on Effects of Tongjiang Granule in Treating Nonerosive Reflux Disease Overlapping Epigastric Pain Syndrome
NCT05312463 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2